Comparative Pharmacology
Head-to-head clinical analysis: MANGANESE CHLORIDE versus SELENIOUS ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANGANESE CHLORIDE versus SELENIOUS ACID.
MANGANESE CHLORIDE vs SELENIOUS ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Manganese is an essential trace element that acts as a cofactor for numerous enzymes, including arginase, glutamine synthetase, superoxide dismutase (Mn-SOD), and various kinases and transferases. It is critical for amino acid, lipid, and carbohydrate metabolism, as well as bone development and wound healing.
Selenious acid is a source of selenium, an essential trace element that is a component of glutathione peroxidase and other selenoproteins, which protect cells from oxidative damage by reducing hydrogen peroxide and organic hydroperoxides.
0.1-0.2 mg/kg manganese as manganese chloride intravenously daily as a component of parenteral nutrition, typically added to total parenteral nutrition (TPN) solutions; usual adult dose: 0.5-1 mg elemental manganese per day.
Selenious acid: 100-200 mcg intravenously over 30 minutes once daily or as directed by clinical response and serum selenium levels.
None Documented
None Documented
Terminal elimination half-life ranges from 2 to 4 weeks (mean ~20 days) for total manganese; reflects slow turnover in tissues, particularly bone and brain.
Terminal elimination half-life is approximately 11 hours for selenium; however, selenious acid itself is rapidly converted to selenide, with a half-life of less than 2 hours. Clinical context: Half-life may be prolonged in renal impairment.
Primarily fecal (biliary) elimination (~80-90%); renal excretion accounts for ~10-20% of total manganese elimination.
Primarily renal; urinary excretion accounts for approximately 50-70% of elimination. Fecal excretion is minor (less than 10%).
Category C
Category C
Trace Element
Trace Element